

Day 1, 25th October, 2025 (Hall A)

Symposium on Metabolic dysfunction–associated steatotic liver disease (MASLD)

Spot Registration - 07:30 am Onwards

Time

Deliberation

10.00 AM - 11.15 AM Session 1 -Epidemiology and Nomenclature

10.00 AM - 11.15 AM	Steatotic Liver Disease nomenclature and burden in India (15 min)
10.15 AM - 10.30 AM	MetALD and usefulness of biomarkers of alcoholism for stratification (15 min)
10.30 AM - 10.45 AM	Lean MASH- How it is different? (15 min)
10.45 AM - 11.00 AM	MASH in children and adolescents: is it different from adults? (15 min)
11.00 AM - 11.15 AM	Combined discussion (15 min)

11.15 AM - 11.45 AM
(30 min)

Inauguration

11.45 AM - 12.00 PM
(15 min)

Tea break

12.00 PM - 1.00 PM

Session 2 - Pathophysiology and therapeutic targets

12.00 PM - 12.15 PM	Adipocyte dysfunction in MASLD (15 min)
12.15 PM - 12.30 PM	Common mechanisms of obesity, metabolic syndrome, and MASLD (15 min)
12.30 PM - 12.45 PM	Genetics of MASLD - Clinical relevance (15 min)
12.45 PM - 01.00 PM	Combined discussion (15 min)

01.00 PM - 2.00 PM

Session 3 - MASLD severity assessment

01.00 PM - 01.15 PM	Body composition analysis and its relevance in MASLD (15 min)
01.15 PM - 01.30 PM	Non-invasive assessment of liver in MASLD (15 min)
01.30 PM - 01.45 PM	Indications of liver biopsy in era of non-invasive tests to assesses MASLD (15 min)
01.45 PM - 02.00 PM	Combined discussion (15 min)

02.00 PM - 03.00 PM
(60 min)

Lunch Break

Day 1, 25th October, 2025 (Hall A)

Symposium on Metabolic dysfunction–associated steatotic liver disease (MASLD)

Time

Deliberation

03.00 PM - 04.00 PM Session 4 - Nonpharmacological intervention for MASLD

03.00 PM - 03.15 PM	Circadian malalignment and time restricted eating in MASLD: Time to reset the liver clock? (15 min)
03.15 PM - 03.30 PM	Impact of nutritional interventions on MASLD: How much to expect? (15 min)
03.30 PM - 03.45 PM	Technology and AI use for MASLD patients to optimize the outcome. (15 min)
03.45 PM - 04.00 PM	Combined discussion (15 min)

04.00 PM - 05.00 PM Session 5 - Specific pharmacological interventions for MASLD

04.00 PM - 04.15 PM	Saroglitazar in MASLD: Evidence so far (15 min)
04.15 PM - 04.30 PM	Vitamin E: Tocopherol vs Tocotrienol (15 min)
04.30 PM - 04.45 PM	Hypothyroidism and Resmetirom in MASLD (15 min)
04.45 PM - 05.00 PM	Combined discussion (15 min)

05.00 PM - 05.15 PM
(15 min)

Tea break

05.15 PM - 06.15 PM Session 6 - Other pharmacological interventions

05.15 PM - 05.30 PM	Anti-obesity drugs in MASLD (15 min)
05.30 PM - 05.45 PM	Obesity treatment in MASLD related compensated cirrhosis: Pros, cons, and methods for weight loss. (15 min)
05.45 PM - 06.00 PM	Upcoming drugs other than GLP-1 and PPAR agonists for MASLD likely to enter in clinical practice (15 min)
06.00 PM - 06.15 PM	Combined discussion (15 min)

06.15 PM - 06.45 PM Session 7 - Panel discussion

06.15 PM - 06.45 PM	Tackling MASLD in the state of Uttar Pradesh by inclusion in National Program (30 min)
---------------------	--

Dinner 7:00 PM onwards & End of Day 1

Day 2, 26th October, 2025 (Hall A)

Spot Registration - 07:30 am Onwards

Time	Deliberation
------	--------------

09.30 AM - 10.30 AM Session 1 - Hepatocellular Carcinoma (HCC)

09.30 AM - 09.42 AM	Screening and diagnostic strategies for HCC (12 min)
09.42 AM - 09.54 AM	HCC in MASLD - How is it different? (12 min)
09.54 AM - 10.06 AM	Locoregional therapies in treatment of HCC (12 min)
10.06 AM - 10.18 AM	Immunotherapy in HCC (12 min)
10.18 AM - 10.30 AM	Liver transplantation in HCC- current status (12 min)
10.30 AM - 10.42 AM	Combined discussion (12 min)

10.42 AM - 11.30 AM Session 2 - Acute on chronic liver failure (ACLF)

10.42 AM - 10.54 AM	Organ failures in ACLF- Consensus and differences (12 min)
10.54 AM - 11.06 AM	Assessment of severity and prognostication in ACLF (12 min)
11.06 AM - 11.18 AM	Novel therapies for treatment of ACLF (12 min)
11.18 AM - 11.30 AM	Liver transplantation in ACLF- recent updates (12 min)
11.30 AM - 11.42 AM	Combined discussion (12 min)

11.42 AM - 12.00 PM

Tea break

12.00 PM - 1.00 PM Session 3 - Complications in cirrhosis

12.00 PM - 12.12 PM	Management of refractory variceal bleeding (12 min)
12.12 PM - 12.24 PM	HRS- AKI- diagnosis and management (12 min)
12.24 PM - 12.36 PM	Fungal and MDR bacterial infections in cirrhosis- diagnosis and management (12 min)
12.36 PM - 12.51 PM	Altered sensorium in liver cirrhosis: causes other than hepatic encephalopathy (15 min)
12.51 PM - 1.00 PM	Combined discussion (9 min)

Day 2, 26th October, 2025 (Hall A)

Time

Deliberation

01.00 PM - 02.00 PM

Session 4 - Alcohol related liver disease

1.00 PM - 1.12 PM

Diagnosis and management of alcohol use disorder (12 min)

1.12 PM - 1.24 PM

Predictors of severity and response in SAH (12 min)

1.24 PM - 1.36 PM

Severe alcoholic hepatitis- recent advances in management (12 min)

1.36 PM - 1.48 PM

Role of nutritional therapy and alcohol abstinence in SAH (12 min)

1.48 PM - 2.00 PM

Combined discussion (12 min)

02.00 PM - 03.00 PM
(60 min)

Lunch Break

03.00 PM - 04.00 PM

Session 5 - Vascular disorders of liver

3.00 PM - 3.12 PM

PSVD- diagnosis and management (12 min)

3.12 PM - 3.24 PM

Non-tumoral PVT- treatment options (12 min)

3.24 PM - 3.36 PM

Management of HVOTO (12 min)

3.36 PM - 3.48 PM

Newer oral anticoagulants versus traditional anticoagulants in liver disease patients (12 min)

3.48 PM - 4.00 PM

Combined discussion (12 min)

04.00 PM - 05.00 PM

Session 6 - Miscellaneous

4.00 PM - 4.12 PM

AI in liver diseases- a beginner's guide (12 min)

4.12 PM - 4.24 PM

Nutrition in cirrhosis- why is it important? (12 min)

4.24 PM - 4.36 PM

Difficult to treat AIH (12 min)

4.36 PM - 4.48 PM

Scope of EUS in liver disease (12 min)

4.48 PM - 5.00 PM

Combined discussion (12 min)

Tea & End of Day 2